PHAR
Pharming Group N.V.
$12.60
-1.64%
$889.9M
No data for this timeframe.
Vol
Market Cap$889.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders1 funds
Inst. Value$136.1K
Inst. Activity1 buys / 0 sells
SEC Reports3
Recent Activity
May 22, 2026
SEC
Pharming announces that the European Commission has granted marketing authorization for Joenja (leniolisib) as the first
6-K — Impact 7/10
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Leniolisib (Phase 3)
Trial: Pediatric Patients Aged 1 to 6 Years With APDS
Sponsor: Pharming Technologies B.V.
Phase: Pha
Apr 16, 2026
SEC
Pharming Group N.V. announced the date and agenda for its 2026 Annual General Meeting of Shareholders (AGM). The meeting
6-K — Impact 3/10
Mar 27, 2026
SEC
Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hum
6-K — Impact 8/10
Inst.
MORGAN STANLEY — ADD
7,700 shares ($136.1K)
Inst.
MORGAN STANLEY — ADD
4,355 shares ($63.1K)
Price Targets
$34.35
+172.6% upside
Strong Buy
Current $12.60
Low $23.40
Median $37.00
High $40.00
4 analysts
$23.40
$40.00
Analyst Ratings
7Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 13, 2026 | Oppenheimer | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.06 ▲ +463.3% | $0.01 — $0.13 | 839% YoY | 3 |
| Next Q | $0.07 ▲ +657.9% | $0.02 — $0.17 | 620% YoY | 3 |
| Current FY | $0.20 ▲ +480.7% | $0.05 — $0.48 | 401% YoY | 3 |
| Next FY | $0.29 ▲ +616.9% | $0.05 — $0.74 | 45% YoY | 3 |
Latest Reports
BULLISH
6-K
7/10
Pharming announces that the European Commission has granted marketing authorization for Joenja (leniolisib) as the first
May 22, 2026
NEUTRAL
6-K
3/10
Pharming Group N.V. announced the date and agenda for its 2026 Annual General Meeting of Shareholders (AGM). The meeting
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $136.1K | ADD |
1 institutional holders with $136.1K total value (7,700 shares) as of 2025-Q4. Top holders: MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 7,700 | $136.1K | 100.0% | ADD +76.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 4,355 | 7,700 | +76.8% | $136.1K | 2025-Q4 |
| MORGAN STANLEY | ADD | 2,900 | 4,355 | +50.2% | $63.1K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BULLISH
6-K
7/10
Pharming announces that the European Commission has granted marketing authorization for Joenja (leni
May 22, 2026
NEUTRAL
6-K
3/10
Pharming Group N.V. announced the date and agenda for its 2026 Annual General Meeting of Shareholder
Apr 16, 2026
BULLISH
6-K
8/10
Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medici
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 7 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.35 mean target
+172.6% upside
Strong Buy (3.00)
$23.40 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $12.60 |
| Target Low | $23.40 |
| Target Mean | $34.35 |
| Target Median | $37.00 |
| Target High | $40.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.06 | $0.01 | $0.13 | 838.8% | +463.3% | — | $0.1B | 8.6% | 3 |
| Next Q 2026-09-30 |
$0.07 | $0.02 | $0.17 | 620.0% | +657.9% | — | $0.1B | 12.8% | 3 |
| Current FY 2026-12-31 |
$0.20 | $0.05 | $0.48 | 400.8% | +480.7% | — | $0.4B | 7.3% | 3 |
| Next FY 2027-12-31 |
$0.29 | $0.05 | $0.74 | 44.9% | +616.9% | — | $0.4B | 11.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.056 | |
| 7d ago | $0.040 | +0.016 |
| 30d ago | $0.010 | +0.046 |
| 60d ago | $0.010 | +0.046 |
| 90d ago | $0.010 | +0.046 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2026 | Oppenheimer | REITERATE | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 27, 2026
Clinical Trial
Pediatric Patients Aged 1 to 6 Years With APDS
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Leniolisib (Phase 3)
Trial: Pediatric Patients Aged 1 to 6 Years With APDS
Sponsor: Pharming Technologies B.V.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditions: A
Apr 22, 2026
Clinical Trial
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
Phase Phase 2 — COMPLETED
Apr 20, 2026
clinical_trial_readout
T-90d Trial Readout: Leniolisib (Phase 3)
Trial: Pediatric Patients Aged 1 to 6 Years With APDS
Sponsor: Pharming Technologies B.V.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditions: A
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: Leniolisib (Phase 3)
Trial: Pediatric Patients Aged 1 to 6 Years With APDS
Sponsor: Pharming Technologies B.V.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditions: A
Apr 10, 2026
clinical_trial_readout
T-90d Trial Readout: Leniolisib (Phase 3)
Trial: Pediatric Patients Aged 1 to 6 Years With APDS
Sponsor: Pharming Technologies B.V.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditions: A
Apr 1, 2026
Clinical Trial
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Phase Phase 3 — TERMINATED